文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

不同滤器对脓毒症相关急性肾损伤患者疗效的影响

[Effect of different filters on the efficacy in patients with sepsis-associated acute kidney injury].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2025-01-01
一句话结论oXiris滤器行CRRT可降低SA-AKI患者7天病死率(16.7% vs 42.9%),并降低炎症介质、改善血流动力学,28天病死率无显著差异。

该前瞻性研究纳入宁夏医科大学总医院重症医学科2022年8月至2023年10月收治的65例首次行CRRT的SA-AKI患者,随机分为oXiris滤器组(30例)和普通滤器组(35例),首次治疗时间≥36小时。oXiris组7天病死率显著低于普通滤器组[16.7%(5/30)vs. 42.9%(15/35),P<0.05],28天病死率两组无显著差异[36.7%(11/30)vs. 54.3%(19/35),P>0.05]。治疗后48小时oXiris组hs-CRP、SOFA评分、去甲肾上腺素剂量显著低于普通滤器组,MAP显著升高(均P<0.05)。作者认为oXiris滤器在CRRT治疗中较常规滤器显示出治疗优势。

要点

  • oXiris组7天病死率16.7%(5/30)显著低于普通滤器组42.9%(15/35),P<0.05。
  • 28天病死率oXiris组36.7%(11/30) vs. 普通滤器组54.3%(19/35),P>0.05,无显著差异。
  • 治疗48小时后oXiris组hs-CRP[87.2(74.2,126.0)mg/L vs. 157.0(88.0,200.0)mg/L]、SOFA评分[11.0(10.0,12.0) vs. 12.0(10.0,14.0)]、去甲肾上腺素剂量(0.51±0.37 vs. 0.81±0.58 μg×kg⁻¹×min⁻¹)均显著低于普通滤器组,均P<0.05。
  • 治疗48小时后oXiris组MAP显著高于普通滤器组(82.00±8.71 mmHg vs. 77.77±7.80 mmHg,P<0.05)。
  • oXiris组治疗24小时后hs-CRP、PCT、IL-6、SOFA评分、MAP、去甲肾上腺素剂量较治疗前均有统计学意义(均P<0.05)。

适用人群与场景

  • 宁夏医科大学总医院重症医学科2022年8月至2023年10月收治的脓毒症相关急性肾损伤(SA-AKI)首次行CRRT的患者。
  • 所有患者接受抗感染、优化容量管理及器官功能支持等常规治疗。

处置流程与药物剂量

  • 在常规治疗基础上,观察组使用oXiris滤器行CRRT,对照组使用普通滤器行CRRT,首次治疗时间≥36小时。
  • CRRT治疗前及治疗24小时、48小时收集hs-CRP、PCT、IL-6、SOFA评分、MAP、血乳酸、去甲肾上腺素剂量等指标。

研究设计与关键结果

  • 前瞻性研究,最终纳入65例SA-AKI患者,观察组30例、对照组35例;两组年龄、性别、AKI分期、感染来源等基线资料无显著差异。
  • 观察组7天病死率显著低于对照组[16.7%(5/30) vs. 42.9%(15/35),P<0.05];28天病死率两组无显著差异[36.7%(11/30) vs. 54.3%(19/35),P>0.05]。
  • 治疗前两组炎症指标、SOFA评分、MAP、血乳酸、去甲肾上腺素剂量无显著差异;治疗24小时和48小时后两组血流动力学较治疗前稳定,炎症指标、SOFA评分、血乳酸、去甲肾上腺素剂量有不同程度下降,MAP显著升高。
  • 观察组治疗24小时后hs-CRP、PCT、IL-6、SOFA评分、MAP、去甲肾上腺素剂量与治疗前比较均有统计学意义[hs-CRP(mg/L):125.0(105.0,171.2) vs. 280.5(213.2,313.8),PCT(μg/L):51.0(20.0,62.8) vs. 71.0(10.8,100.0),IL-6(ng/L):1762.2(300.8,4327.5) vs. 4447.5(630.4,5000.0),SOFA评分:13.0(12.0,14.0) vs. 16.0(15.0,17.0),MAP(mmHg):79.00±12.87 vs. 65.20±11.70,去甲肾上腺素剂量(μg×kg⁻¹×min⁻¹):0.82±0.33 vs. 1.63±0.51,均P<0.05]。
  • 对照组治疗48小时后PCT和MAP与治疗前比较有统计学意义。
  • 与对照组比较,观察组治疗48小时后hs-CRP、SOFA评分和去甲肾上腺素剂量显著降低[hs-CRP(mg/L):87.2(74.2,126.0) vs. 157.0(88.0,200.0),SOFA评分:11.0(10.0,12.0) vs. 12.0(10.0,14.0),去甲肾上腺素剂量(μg×kg⁻¹×min⁻¹):0.51±0.37 vs. 0.81±0.58,均P<0.05],MAP显著升高(mmHg:82.00±8.71 vs. 77.77±7.80,P<0.05)。

证据类型、等级与局限

  • 证据类型:前瞻性研究。
  • 作者结论:oXiris滤器行CRRT可降低SA-AKI患者短期病死率、降低炎症介质水平并改善血流动力学,较常规滤器显示出治疗优势。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在SA-AKI患者CRRT治疗中,oXiris滤器较常规滤器可降低短期(7天)病死率、降低炎症介质水平并改善血流动力学,显示出治疗优势。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the effects of using different filters in continuous renal replacement therapy (CRRT) on the mortality, inflammatory mediator level and hemodynamics in patients with sepsis-associated acute kidney injury (SA-AKI).

METHODS: A prospective study was conducted. The patients with SA-AKI undergoing first CRRT admitted to the critical care medicine department of General Hospital of Ningxia Medical University from August 2022 to October 2023 were enrolled as the study objects, and they were divided into observation group and control group by random number table method. All patients received routine treatment including anti-infection, optimized volume management and organ function support. On this basis, the observation group was treated with oXiris filter for CRRT, while the control group was treated with ordinary filter for CRRT, and the first treatment time was ≥ 36 hours. General data of the two groups were collected and compared. At the same time, the inflammatory indicators [high-sensitivity C-reactive protein (hs-CRP), procalcitonin (PCT), interleukin-6 (IL-6)], sequential organ failure assessment (SOFA) score, mean arterial pressure (MAP), blood lactic acid (Lac), noradrenaline dosage and other related indicators were collected before CRRT treatment and 24 hours and 48 hours after treatment, and the 7-day and 28-day mortality of patients were recorded.

RESULTS: Finally, 65 patients were enrolled, including 30 in the observation group and 35 in the control group. There were no significant differences in baseline data including age, gender, acute kidney injury (AKI) stage and infection source between the two groups. The 7-day mortality of observation group was significantly lower than that of control group [16.7% (5/30) vs. 42.9% (15/35), P < 0.05]. There was no significant difference in 28-day mortality between the observation group and the control group [36.7% (11/30) vs. 54.3% (19/35), P > 0.05]. There were no significant differences in inflammation indicators, SOFA score, MAP, Lac and norepinephrine dosage before treatment between the two groups. After 24-hour and 48-hour treatment, the hemodynamics of the two groups were stable compared with before treatment, the inflammatory indicators, SOFA score, Lac and norepinephrine dosage were reduced to varying degrees, and MAP was significantly increased. In the observation group, hs-CRP, PCT, IL-6, SOFA score, MAP, and norepinephrine dosage showed statistical significance at 24 hours after treatment as compared with before treatment [hs-CRP (mg/L): 125.0 (105.0, 171.2) vs. 280.5 (213.2, 313.8), PCT (μg/L): 51.0 (20.0, 62.8) vs. 71.0 (10.8, 100.0), IL-6 (ng/L): 1 762.2 (300.8, 4 327.5) vs. 4 447.5 (630.4, 5 000.0), SOFA score: 13.0 (12.0, 14.0) vs. 16.0 (15.0, 17.0), MAP (mmHg, 1 mmHg ≈ 0.133 kPa): 79.00±12.87 vs. 65.20±11.70, norepinephrine dosage (μg×kg-1×min-1): 0.82±0.33 vs. 1.63±0.51, all P < 0.05]. In the control group, PCT and MAP showed statistical significance after 48 hours of treatment as compared with before treatment. Compared with the control group, hs-CRP, SOFA score and norepinephrine dosage after 48 hours of treatment in the observation group were significantly decreased [hs-CRP (mg/L): 87.2 (74.2, 126.0) vs. 157.0 (88.0, 200.0), SOFA score: 11.0 (10.0, 12.0) vs. 12.0 (10.0, 14.0), norepinephrine dosage (μg×kg-1×min-1): 0.51±0.37 vs. 0.81±0.58, all P < 0.05], MAP was significantly increased (mmHg: 82.00±8.71 vs. 77.77±7.80, P < 0.05).

CONCLUSION: In the treatment of CRRT, oXiris filter can reduce the short-term mortality of SA-AKI patients, lower inflammatory mediators levels and improve hemodynamics, showing therapeutic advantages over conventional filters.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Zhou W, Zhao T, Ma Q, et al. [Effect of different filters on the efficacy in patients with sepsis-associated acute kidney injury]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 39968586. doi:10.3760/cma.j.cn121430-20240802-00661

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。